Table 1.
Association between genetic polymorphisms in the IGF-1 and IGF-2 genes and breast cancer risk
| Marker | Allele* | Location | MAF† | Genotype frequency ‡ | p-value§ | Odd ratios (95% CIs)∥ | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| AA | AB | BB | AA | AB | BB | |||||
| IGF-1 | ||||||||||
| rs9919733 | A/G | Promoter | 0.28 | 0.52 | 0.41 | 0.07 | 0.69 | 1.0 | 0.9 (0.7–1.0) | 1.1 (0.8–1.5) |
| rs35767 | C/T | Promoter | 0.34 | 0.42 | 0.47 | 0.11 | 0.20 | 1.0 | 0.8 (0.7–1.0) | 1.0 (0.8–1.4) |
| rs12579108 | A/T | Promoter | 0.28 | 0.49 | 0.43 | 0.07 | 0.50 | 1.0 | 0.8 (0.7–1.0) | 1.2 (0.8–1.6) |
| rs2288377 | C/A | Promoter | 0.29 | 0.50 | 0.42 | 0.08 | 0.04 | 1.0 | 0.8 (0.7–1.0) | 1.1 (0.8–1.5) |
| rs2162679 | A/G | intron | 0.35 | 0.41 | 0.48 | 0.11 | 0.19 | 1.0 | 0.8 (0.7–1.0) | 1.0 (0.8–1.4) |
| rs5742615 | C/A | intron | 0.27 | 0.52 | 0.41 | 0.07 | 0.24 | 1.0 | 1.1 (0.8–1.5) | 1.0 (0.8–1.4) |
| rs12821878 | G/A | intron | 0.05 | 0.91 | 0.08 | 0.01 | 0.23 | 1.0 | 1.0 (0.8–1.2) | 1.3 (0.4–4.7) |
| rs7956547 | T/C | intron | 0.16 | 0.71 | 0.26 | 0.03 | 0.68 | 1.0 | 0.8 (0.7–1.0) | 1.2 (0.7–2.0) |
| rs2195239 | G/C | intron | 0.43 | 0.32 | 0.50 | 0.18 | 0.57 | 1.0 | 1.0 (0.8–1.2) | 0.9 (0.7–1.2) |
| rs4764697 | C/T | intron | 0.16 | 0.71 | 0.26 | 0.03 | 0.94 | 1.0 | 0.9 (0.7–1.1) | 1.0 (0.6–1.7) |
| rs5742692 | T/C | intron | 0.26 | 0.53 | 0.41 | 0.06 | 0.18 | 1.0 | 0.9 (0.8–1.1) | 1.1 (0.8–1.6) |
| rs978458 | C/T | intron | 0.42 | 0.33 | 0.49 | 0.18 | 0.81 | 1.0 | 0.8 (0.7–1.0) | 1.0 (0.8–1.3) |
| rs6220 | T/C | 3’ UTR | 0.42 | 0.33 | 0.49 | 0.18 | 0.94 | 1.0 | 1.0 (0.8–1.2) | 1.0 (0.8–1.3) |
| Rs6218 | T/C | 3’ UTR | 0.25 | 0.55 | 0.39 | 0.06 | 0.59 | 1.0 | 1.0 (0.8–1.1) | 1.1 (0.8–1.7) |
| rs6214 | G/A | 3’ UTR | 0.48 | 0.27 | 0.50 | 0.23 | 0.88 | 1.0 | 1.0 (0.8–1.2) | 0.9 (0.7–1.1) |
| rs5742723 | C/A | 3’ UTR | 0.28 | 0.51 | 0.42 | 0.07 | 0.10 | 1.0 | 0.9 (0.8–1.1) | 1.2 (0.8–1.6) |
| rs2946834 | C/T | 3’ UTR | 0.46 | 0.29 | 0.50 | 0.21 | 0.54 | 1.0 | 1.0 (0.8–1.2) | 1.0 (0.8–1.3) |
| rs6219 | C/T | 3’ UTR | 0.16 | 0.70 | 0.27 | 0.03 | 0.49 | 1.0 | 1.0 (0.8–1.2) | 0.9 (0.6–1.5) |
| rs10860861 | T/C | 3’ UTR | 0.38 | 0.38 | 0.47 | 0.15 | 0.93 | 1.0 | 1.0 (0.8–1.2) | 1.1 (0.8–1.4) |
| rs10860862 | C/T | 3’ UTR | 0.16 | 0.70 | 0.28 | 0.02 | 0.47 | 1.0 | 0.9 (0.8–1.1) | 0.9 (0.5–1.6) |
| IGF-2 | ||||||||||
| rs734351 | C/T | intron | 0.22 | 0.56 | 0.38 | 0.06 | 0.70 | 1.0 | 1.1 (0.9–1.3) | 1.1 (0.8–1.6) |
| rs3802971 | C/T | 3’ UTR | 0.17 | 0.69 | 0.28 | 0.03 | 0.51 | 1.0 | 1.0 (0.8–1.2) | 1.4 (1.5–1.2) |
| rs2585 | T/C | 3’ UTR | 0.44 | 0.33 | 0.46 | 0.21 | 0.25 | 1.0 | 1.0 (0.8–1.2) | 1.2 (0.9–1.5) |
*
Major allele is in bold
†
Minor allele frequency (MAF) based on 1,110 cases and 1,203 controls
‡
For SNP, AA, major allele homozygote, AB, heterozygote, BB, minor allele homozygote, among controls
§
P-value is the probability of the Chi-square test for Hardy Weinberg disequilibrium among controls
∥
Logistic regression models conditioned on age, and adjusted for menopausal status, age at menarche, and age at first full term pregnancy.